Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...
Johnson & Johnson (J&J) has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies ...
Navi Mumbai: A medical procedure to treat cancers of blood like leukaemia and lymphoma was successfully used on a 57-year-old ...
Matias Sanchez, MD, assistant professor in the Department of Medicine, Division of Hematology and Oncology, University of Illinois Chicago, emphasizes the importance of patient education and caregiver ...
Despite challenges such as high attrition rates and adverse events, the trial highlights the value of established therapies ...
Extends Gratitude to Outgoing Board Members for Their Years of Dedicated Service to the IMF BoardSTUDIO CITY, Calif., Nov. 26 ...
Researchers at the Icahn School of Medicine at Mount Sinai have discovered how genetics can affect the success of venetoclax, ...
Given the complexity of his medical condition, traditional blood transfusions posed significant risks. Understanding these ...
Barclays raised the firm’s price target on Arcellx (ACLX) to $115 from $73 and keeps an Overweight rating on the shares following a transfer of ...
GlobalData on MSN5d
GSK eyes up combo approval for previously withdrawn myeloma drugThe US Food and Drug Administration (FDA) is expected to make a Prescription Drug User Fee Act (PDUFA) decision by mid-2025.
The following is a summary of “Daratumumab-based regimen for newly diagnosed multiple myeloma patients with paraskeletal ...
Janssen Research & Development was granted FDA orphan designation for a treatment of multiple myeloma, according to a post to the agency’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback